8th April 2021 – (Hong Kong) After the European Medicines Agency discovered a possible connection between AstraZeneca’s COVID-19 vaccine and thrombosis, many local experts suggested that the Hong Kong government should not purchase AstraZeneca vaccine instead. However, AstraZeneca said that the current plan remains unchanged, and it will continue to work closely with the Hong Kong and Macau governments, and in accordance with the agreement to provide Hong Kong and Macau citizens with AstraZeneca’s COVID-19 vaccine. The pharmaceutical company said that it has been actively cooperating with regulatory agencies to change relevant product information, and is also understanding individual cases, epidemiology, and looking for possible mechanisms that can explain these rare events.
The Food and Health Bureau did not respond positively to whether the procurement of AstraZeneca vaccines should be suspended. It only stated that the Department of Health has not yet received applications from relevant pharmaceutical companies to approve its COVID-19 vaccine under the regulations and will pay close attention to other drug regulatory authorities’ announcements. It will continue to contact the pharmaceutical factory to obtain relevant safety information.